CSL511 Fibrinogen concentrate (human)

Phase 3Biologic

CSL511 Fibrinogen concentrate (human) is one of 13 biologic programs targeting Pseudomyxoma Peritonei. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pseudomyxoma PeritoneiActive, not recruiting

Pseudomyxoma PeritoneiPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Pseudomyxoma Peritonei

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Mitosol

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 2

1 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 5

FOLFOX

AstraZeneca

Phase 2

1 6

Cryoprecipitate

CSL Behring

Phase 3

1 7

Beyfortus

BeiGene

Phase 1

1 8

Cysteine Hydrochloride

Novartis

Phase 1

1 9

CSL511 Fibrinogen concentrate (human)

CSL Behring

Phase 3

1 10

Intraperitoneal 5FU

WWashington University School of Medicine

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Pseudomyxoma Peritonei

NCT06617897

Clinical

Trials by Indication[1]

Pseudomyxoma Peritonei1 trial

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Recruiting· CSL Behring logo

CSL Behring·Phase 3·NCT06617897·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CSL511 Fibrinogen concentrate (human). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSL511 Fibrinogen concentrate (human) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSL511 Fibrinogen concentrate (human). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

CSL511 Fibrinogen concentrate (human)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Pseudomyxoma Peritonei1 trial

References

Drug Info

Quick Facts

Related News